Intravenous Methylprednisolone in Guillain–Barré syndrome: The Way to Go Further

I read with great interest the paper by Prasad et al. [1] analyzing the potential role of intravenous methylprednisolone (IVMP) in the treatment of Guillain-Barr syndrome (GBS).The authors concluded that "From the above, it is clear that IVMP is potentially an effective option for GBS.This is supported by strong biological rationale for use of corticosteroid in GBS, similar to that in many autoimmune diseases.It may be noted that both studies used a dose of IVMP 500 mg daily for 5 days.Current practice is mostly to use 1 g daily for 3-5 days, which may have relatively larger effect than using 500 mg daily for 5 days.This is of potentially substantial clinical value, especially in those settings with limited access to intravenous immunoglobulin or plasmapheresis."I wish to add a pathogenic indication of IVMP in early classic GBS (10 days after symptom onset) and in its very early stage (4 days). [2]